The American Thyroid Association recently classified all MEN2A-associated codons into increasing risk levels A-C and stated that some patients may delay prophylactic thyroidectomy if certain criteria are met. One criterion is a less aggressive family history of MTC but whether families with the same mutated codon have variable MTC aggressiveness is not well described. We developed several novel measures of MTC aggressiveness and compared families with the same mutated codon to determine if there is significant inter-familial variability. Pedigrees of families with MEN2A were reviewed for codon mutated and proportion of RET mutation carriers with MTC. Individuals with MTC were classified as having local or distant MTC and whether they had pr...
Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant cancer predisposition syndrome,...
Multiple Endocrine Neoplasia 2 (MEN2) is a hereditary cancer syndrome for developing medullary thyro...
Germline RET variants are responsible for approximately 25% of medullary thyroid carcinoma (MTC) cas...
The American Thyroid Association recently classified all MEN2A-associated codons into increasing ris...
MEN-2A is characterized by medullary thyroid carcinoma (MTC) with pheochromocytoma and sometimes par...
Twenty-five percent of medullary thyroid cancers (MTC) are familial and inherited as an autosomal do...
Medullary thyroid carcinoma (MTC) accounts for 15% of thyroid cancers. It arises in the C-cells of t...
Medullary thyroid carcinoma (MTC) represents 3-5% of thyroid cancers. 75% is sporadic and 25% is the...
Background Occurrence in a familial setting is well established for medullary thyroid carcinoma (MTC...
Sixty-one heterozygotes harboring the germline V804L mutation of the RET protooncogene were identifi...
The familial risk of medullary thyroid carcinoma (MTC alone or as part of multiple endocrine neoplas...
BACKGROUND: Germline RET gene mutations are causative of multiple endocrine neoplasia (MEN) 2 and m...
Multiple Endocrine Neoplasia 2 (MEN2) is a hereditary cancer syndrome for developing medullary thyro...
Context: Over the last decade, our knowledge of the multiple endocrine neoplasia (MEN) type 2 syndro...
AIM: The nosology of familial medullary thyroid carcinoma (FMTC) has been described as a distinct pa...
Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant cancer predisposition syndrome,...
Multiple Endocrine Neoplasia 2 (MEN2) is a hereditary cancer syndrome for developing medullary thyro...
Germline RET variants are responsible for approximately 25% of medullary thyroid carcinoma (MTC) cas...
The American Thyroid Association recently classified all MEN2A-associated codons into increasing ris...
MEN-2A is characterized by medullary thyroid carcinoma (MTC) with pheochromocytoma and sometimes par...
Twenty-five percent of medullary thyroid cancers (MTC) are familial and inherited as an autosomal do...
Medullary thyroid carcinoma (MTC) accounts for 15% of thyroid cancers. It arises in the C-cells of t...
Medullary thyroid carcinoma (MTC) represents 3-5% of thyroid cancers. 75% is sporadic and 25% is the...
Background Occurrence in a familial setting is well established for medullary thyroid carcinoma (MTC...
Sixty-one heterozygotes harboring the germline V804L mutation of the RET protooncogene were identifi...
The familial risk of medullary thyroid carcinoma (MTC alone or as part of multiple endocrine neoplas...
BACKGROUND: Germline RET gene mutations are causative of multiple endocrine neoplasia (MEN) 2 and m...
Multiple Endocrine Neoplasia 2 (MEN2) is a hereditary cancer syndrome for developing medullary thyro...
Context: Over the last decade, our knowledge of the multiple endocrine neoplasia (MEN) type 2 syndro...
AIM: The nosology of familial medullary thyroid carcinoma (FMTC) has been described as a distinct pa...
Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant cancer predisposition syndrome,...
Multiple Endocrine Neoplasia 2 (MEN2) is a hereditary cancer syndrome for developing medullary thyro...
Germline RET variants are responsible for approximately 25% of medullary thyroid carcinoma (MTC) cas...